Pembrolizumab Global Buyers List: Comprehensive Guide to Keytruda Importers & Procurement Trends

Pembrolizumab, marketed globally as Keytruda by Merck & Co., stands as the world’s leading immune checkpoint inhibitor and one of the best-selling pharmaceutical products in history. With global sales projected to reach approximately $33.8 billion in 2026, the drug’s procurement ecosystem spans hospitals, specialty pharmacies, government health ministries, and pharmaceutical distributors across more than 60 countries. This comprehensive guide provides an up-to-date Pembrolizumab global buyers list, regional procurement analysis, and strategic insights into the evolving sourcing landscape—critical intelligence for pharmaceutical suppliers, distributors, and supply chain professionals navigating this $31–34 billion market.

Global Market Overview & Procurement Landscape
Top Pembrolizumab Buyers & Importers by Region
Keytruda Supply Chain & Distribution Channels
Biosimilar Market Entry & Future Procurement Shifts
Strategic Sourcing Insights for Buyers & Suppliers

1. Global Market Overview & Procurement Landscape

1.1 Market Size and Growth Trajectory

The global pembrolizumab market demonstrates remarkable scale and continued expansion. Market valuation estimates for 2025 range from $31.4 billion to $34.29 billion, with projections indicating growth to $32.7–$33.1 billion in 2026. Long-term forecasts vary based on patent expiration timelines and biosimilar market entry, with some projections showing continued growth to $41.1 billion by 2034, while others anticipate a gradual decline to approximately $25.0 billion by 2033 as biosimilar competition intensifies.

1.2 Key Market Drivers

Several factors sustain robust global demand for pembrolizumab:

Expanding Approved Indications: Keytruda holds over 30 FDA- and EMA-approved oncology indications across multiple cancer types, including non-small cell lung cancer, melanoma, urothelial carcinoma, head and neck squamous cell carcinoma, gastric cancer, cervical cancer, and triple-negative breast cancer.
Rising Global Cancer Incidence: Increasing cancer prevalence worldwide, particularly in Asia-Pacific and Latin America, continues to drive procurement volumes .
New Formulation Launches: The recent introduction of subcutaneous pembrolizumab (KEYTRUDA QLEX) is expected to enhance patient convenience and expand market accessibility.
Combination Therapy Adoption: Growing clinical adoption of pembrolizumab in combination with chemotherapy and other targeted therapies broadens its therapeutic footprint.

1.3 Regional Market Dominance

North America leads global pembrolizumab consumption with approximately 38% revenue share, driven by high cancer prevalence, favorable reimbursement policies, and extensive oncology infrastructure . Asia-Pacific represents the fastest-growing regional market, with a projected CAGR of 6.40% through 2033, fueled by expanding oncology treatment infrastructure and increasing regulatory approvals across China, Japan, and India.

2. Top Pembrolizumab Buyers & Importers by Region

2.1 Buyers Sourcing from India

Based on Indian Customs (DGFT) data covering 215 shipments across 21 countries, 66 active buyers collectively imported $1.9 million worth of pembrolizumab from India. The following represent the top pembrolizumab importers from India:

Rank	Buyer	Country	Import Value	Shipments	Market Share
1	INDIRA GANDHI MEMORIAL HOSPITAL	Maldives	$130.1K	30	6.7%
2	AS PER INVOICE	Brazil	$105.6K	10	5.5%
3	MERMISI LLC	Georgia	$59.9K	6	3.1%
4	KARLENE SMALL	Jamaica	$53.3K	2	2.8%
5	F AGAINST PROFORMA INVOICE	Brazil	$48.9K	5	2.5%

Source: Indian Customs (DGFT), TransData Nexus

Additional notable buyers from India include KEISHA YOUNG-HENRY (Jamaica, $47.8K), RICARDO LUIZ BARBOZA (Brazil, $47.4K), and ERINEA FERRAZ DOS (Brazil, $47.2K).

Key Insight: The top five buyers collectively control 20.6% of total import value from India, reflecting a moderately competitive buyer landscape with significant fragmentation.

2.2 Indian Buyers (Importers)

India itself represents a significant import market for pembrolizumab, sourcing from multiple countries:

From Singapore: MSD PHARMACEUTICALS PRIVATE LIMITED is the sole Indian buyer, importing $85.8 million worth of pembrolizumab across 9 shipments from MERCK SHARP & DOHME ASIA PACIFIC SERVICES PTE LTD. This represents by far the largest single procurement corridor identified in the trade data.

From Germany: Eight Indian buyers imported $788.7K across 33 shipments, with BIO-RAD LABORATORIES (INDIA) PRIVATE LIMITED leading at $523.0K (66.3% share), followed by PAREXEL INTERNATIONAL CLINICAL RESEARCH PRIVATE LIMITED ($164.9K) and INTAS PHARMACEUTICALS LIMITED ($79.8K).

From the United States: Ten Indian buyers sourced $135.4K across 49 shipments from 15 suppliers. Leading buyers include IPCA LABORATORIES LIMITED ($31.0K), INTAS PHARMACEUTICALS LIMITED ($28.9K), and KRISHGEN BIOSYSTEMS ($26.3K).

From the United Kingdom: Key buyers include ASTRAZENECA PHARMA INDIA LIMITED, GSK PHARMA INDIA PRIVATE LIMITED, and DR.REDDY’S LABORATORIES LIMITED.

2.3 Latin American Buyers

Brazil represents a significant and growing market for pembrolizumab procurement:

Brazil imported $860.1K of pembrolizumab from India alone (2022–2026), with 30 distinct buyers supplied by 14 manufacturers.
Top Brazilian importers include TO THE ORDER, RICARDO LUIZ BARBOZA, ERINEA FERRAZ DOS, and ERIKA CARDOSO DA SILVA.
ERINEA FERRAZ DOS is a Brazil-based pharmaceutical buyer specializing in pembrolizumab and injection products, with primary trade routes through Guarulhos port.

Peru: ROCHE FARMA PERU S.A. is an established international procurement company handling pembrolizumab, perjeta, and IVD products through Lima and Callao airports.

Argentina: The Argentine national government significantly increased pembrolizumab procurement, from approximately 280 doses annually to nearly 4,000 doses in 2025—a dramatic increase exceeding 1,300%. Major purchasers include the National Ministry of Health, provincial social security organizations (obras sociales), PAMI, and union health plans.

2.4 Middle Eastern Buyers

The Middle East and North Africa (MENA) region is emerging as a strategic procurement hub:

Avalon Pharma (Saudi Arabia) has secured exclusive rights to register and market pembrolizumab biosimilar across Saudi Arabia and the broader MENA region through a strategic agreement with Bio-Thera Solutions.
UAE: Keytruda is accessible through hospital pharmacies and the Ministry of Health and Prevention (MoHAP) named-patient import framework.
Saudi Arabia: The Saudi Food and Drug Authority (SFDA) operates a named-patient import mechanism allowing licensed physicians to request pembrolizumab for patients.

2.5 African Buyers

South Africa: Pembrolizumab is accessible through the SAHPRA named-patient pathway, with major oncology indications covered across melanoma, non-small cell lung cancer, head-and-neck cancer, and Hodgkin lymphoma. Private insurers including Momentum Health, Bonitas, Medihelp, Profmed, and Polmed provide coverage.

Egypt: MSD Egypt distributes pembrolizumab for EDA-registered indications through major oncology centers including the National Cancer Institute (Cairo University), 57357 Children’s Cancer Hospital, Dar Al Fouad Hospital, and other licensed tertiary centers. Private insurers including MetLife Egypt, AXA Egypt, Bupa Egypt, and Allianz Egypt offer coverage.

Congo: Imports of pembrolizumab primarily originate from France, India, Belgium, Egypt, and Germany.

2.6 European Buyers

Abacus Medicine A/S (Denmark) is a key European distributor and importer of pembrolizumab, with operations across multiple markets.

EUDC European Distribution Center (Germany) serves as a major European supply hub, shipping pembrolizumab to buyers including PAREXEL INTERNATIONAL CLINICAL RESEARCH PRIVATE LIMITED in India.

2.7 Asian Buyers Beyond India

China: Primedomain International Trading Limited is a China-based supplier engaged in pembrolizumab and pharmaceutical raw material exports.

Bangladesh: Drug International Ltd. has imported pembrolizumab from China-based supplier Primedomain International Trading Limited.

Pakistan: 4BF Bioscience Ltd. has engaged in pembrolizumab trade activity.

2.8 Major Pharmaceutical Distributors

Several major pharmaceutical distributors serve as key intermediaries in the pembrolizumab supply chain:

ASD Healthcare and Besse Medical are listed as authorized distributors within the Merck Access Program for KEYTRUDA.
Merck Sharp & Dohme LLC serves as the primary packager and distributor of Keytruda in the United States.
Sutphin Drugs Inc. (United States) has been documented shipping Keytruda (pembrolizumab injection 100mg/4mL) to Indian buyers.

3. Keytruda Supply Chain & Distribution Channels

3.1 Primary Distribution Channels

Hospital pharmacies represent the dominant distribution channel, accounting for 51.1% of the Keytruda market in 2025. Specialty pharmacies and ambulatory infusion centers serve as secondary channels, particularly for outpatient oncology care.

3.2 Procurement Pathways

Pembrolizumab procurement follows several distinct pathways:

Direct Hospital Procurement: Large hospital systems and cancer centers purchase directly from manufacturers or authorized distributors.
Government Tender Systems: National and provincial health ministries issue public tenders for pembrolizumab procurement, as evidenced by Taiwan’s Ministry of Health and Welfare Fongyuan Hospital tender valued at NT$8,524,742.
Named-Patient Import Programs: Many countries operate regulatory frameworks allowing individual patient imports for unregistered indications.
Specialty Pharmacy Networks: Specialty pharmacies serve as intermediaries between manufacturers and healthcare providers.

3.3 Cold Chain Requirements

As a biologic monoclonal antibody, pembrolizumab requires strict cold chain management throughout the supply chain—a critical consideration for procurement professionals. Temperature-controlled logistics, specialized packaging, and validated transport partners are essential for maintaining product integrity.

4. Biosimilar Market Entry & Future Procurement Shifts

4.1 Patent Expiration Timeline

The pembrolizumab patent cliff represents a watershed moment for the global procurement landscape. Core patents are expected to expire around 2028, with major market launches anticipated in 2028–2029.

4.2 Biosimilar Pipeline

Multiple developers are advancing pembrolizumab biosimilars through late-stage clinical trials:

Sandoz Group AG (Switzerland)
Biocon Biologics Limited (India)
Alvotech (Iceland)
Formycon AG (Germany)
Zydus Lifesciences Limited (India)—partnered with Formycon for US and Canada markets
Samsung Bioepis
Celltrion

The biosimilar pipeline segment is projected to be the fastest-growing category with a CAGR of 45.90%. However, as of 2025, no biosimilars have yet launched in the US, EU, or Japan, with Keytruda maintaining over 98% market share in the branded segment.

4.3 Strategic Implications for Buyers

Procurement professionals should consider:

Contract Timing: Long-term supply agreements should account for biosimilar market entry.
Supplier Diversification: The top five suppliers currently control approximately 91% of global revenue. Biosimilar entry will create diversification opportunities.
Pricing Leverage: Biosimilar competition is expected to exert downward pressure on pricing, potentially benefiting buyers.
Supply Chain Resilience: The supply chain window for first-to-market participation in the pembrolizumab biosimilar market has effectively closed for new entrants, suggesting established players have secured positions.

5. Strategic Sourcing Insights for Buyers & Suppliers

5.1 For Buyers

Market Intelligence: Leverage customs data platforms like TransData Nexus and 52wmb.com to identify verified suppliers and benchmark pricing.

Regional Diversification: Consider sourcing from multiple origins. India serves as a significant export hub, while Singapore supplies high-value formulations. Germany and the United States offer diversified supplier bases .

Regulatory Compliance: Ensure all procurement complies with local regulatory frameworks, including named-patient import programs where applicable.

Biosimilar Readiness: Begin evaluating biosimilar suppliers and establish relationships ahead of market entry.

5.2 For Suppliers

Buyer Identification: The 66 active buyers documented in Indian trade data represent just one segment of the global market. Expand research to include hospital systems, government tenders, and specialty pharmacy networks.

Regional Expansion: High-growth regions including Asia-Pacific (6.40% CAGR), Latin America, and the MENA region offer significant opportunity.

Cold Chain Capability: Differentiate through demonstrated cold chain logistics expertise and validated supply chain infrastructure.

Biosimilar Positioning: For biosimilar developers, securing distribution partnerships early (e.g., Avalon Pharma in MENA) will be critical for market access.

MERCK SHARP DOHME PERU S R L
MERCK SHARP AND DOHME COLOMBIA S A S
ICON ANKARA KLINIK ARASTIRMA DIS TICARET ANONIM SIRKETI
GLOBAL MEDICAL LOGISTICS SOCIEDAD ANONIM
MSD PHARMACEUTICALS PRIVATE LIMITED
BỆNH VIỆN UNG BƯỚU
101 SUPPLY CHAIN SOLUTIONS INC
LILLY ILAC TICARET LIMITED SIRKETI
MERCK SHARP DOHME COMERCIALIZADORA S DE RL DE CV
GLOBAL MEDICAL LOGISTICS SOCIEDAD ANONIMA
BỆNH VIỆN UNG BƯỚU HÀ NỘI
BIO RAD LABORATORIES INDIA PRIVATE LIMITED
EPIRUS GLOBAL BUSINESS SOLUTIONS
MERCK SHARP AND DOHME IA LLC
CÔNG TY TNHH ASTRAZENECA VIỆT NAM
MERCK SHARP DOHME I A LLC
FORTREA DEVELOPMENT INDIA PRIVATE LIMITED
ASTRAZENECA PHARMA INDIA LIMITED
CÔNG TY TNHH MSD HH VIỆT NAM
IMPERIAL LIFE SCIENCES PRIVATE LIMITED
INTAS PHARMACEUTICALS LIMITED
QUINTILES CHILE
INC RESEARCH CLINICAL SERVICES MEXICO LIMITED SA DE CV
ROCHE FARMA PERU S A
SIDUS SA
ICON CLINICAL RESEARCH PERU S A
INCEPTA PHARMACEUTICALS LIMITED
GLOBAL MEDICAL LOGISTICS S A
IQVIA TIBBI ISTATISTIK TICARET VE MUSAVIRLIK LIMITED SIRKETI
PAREXEL INTERNATIONAL MEXICO SA DE CV
MARKEN LIMITED SIN TIPO DE SOCIEDAD
LABORATORIOS SIEGFRIED SA
PAREXEL INTERNATIONAL CLINICAL RESEARCH PRIVATE LI
PFIZER SA DE CV
IPCA LABORATORIES LIMITED
BRISTOL MYERS SQUIBB DE MEXICO S DE RL DE CV
CÔNG TY TNHH DƯỢC PHẨM VÀ HÓA CHẤT NAM LINH
GENERICS AFRICA LIMITED
RPS PERU S A C
RS CLINICAL RESEARCH SOLUTIONS MEXICO SA DE CV
SMO TU LOJISTIK VE AMBALAJ SANAYI VE TICARET LIMITED SIRKETI
BỆNH VIỆN K
HEALTHCARE PHARMACEUTICALS LTD
IQVIA RDS PERU S R L
KRISHGEN BIOSYSTEMS PRIVATE LIMITED
ROCHE MUSTAHZARLARI SANAYI ANONIM SIRKETI
ZISKA PHARMACEUTICALSLIMITED
BOEHRINGER INGELHEIM PROMECO SA DE CV
DHL PAKISTAN PRIVATE LIMITED
FISHER BIOPHARMA SERVICES INDIA PVT LTD
HEALTH SERVICES
INVITROGEN BIOSERVICES INDIA PRIVATE LIMITED
MERCK SHARP DOHME ILACLARI LIMITED SIRKETI
PHARMACEUTICAL RESEARCH ASSOCIATES MEXICO S DE RL DE CV
PHARMEVO PRIVATE LIMITED
QUINTILES MEXICO S DE RL DE CV
SHREE KRISHNA LIFECARE
SYNEOS HEALTH MEXICO SA DE CV
BEACON PHARMACEUTICALS PLC
DRUG INTERNATIONAL LIMITED
EVEREST PHARMACEUTICALS LIMITED
LABORATORIOS RICHMOND SACIF
MR FARHAN SHEIKH
NO DISPONIBLE
OXIMIO LOJISTIK VE AMBALAJ SANAYI VE TICARET LIMITED SIRKETI
PAREXEL INTL COLOMBIA S A S
PFIZER SAS
RPS RESEARCH SERVICIOS S DE RL DE CV
ALLIANZ BIOINNOVATION
BARIKI PHARMA GROUP LIMITED
DR REDDY S LABORATORIES LTD
ENZENE BIOSCIENCES LIMITED
ESKAYEF PHARMACEUTICALS LIMITED
JOHNSON JOHNSON PRIVATE LIMITED
LABORATORIO DE PRODUCTOS ETICOS COMERCIAL E INDUSTRIAL SA
PFIZER PFE ILACLARI ANONIM SIRKETI
QUINTILES COLOMBIA LTDA
RELIANCE LIFE SCIENCES PRIVATE LIMITED
REXACORP S A
RPS COL LTDA
ТОВ ІМП ЛОГІСТИКА УКРАЇНА 02094 М КИЇВ ВУЛ ВІСКОЗНА 8
ABBVIE PROD FARMACEUTICOS LTDA
BIOCON BIOLOGICS LIMITED
BIOMEDICAL LIFE SCIENCES
CHOUHAN
DINA KAMRAN
EMERCHEMIE NB CEYLON LTD
FARHANA QAMAR
INFINITE CLINICAL RESEARCH INTERNATIONAL SA DE CV
LAB DIAGNOSTIC SYSTEMS SMC PVT LIMITED
MR ALI FAROOQ
MR LAL MOHAMMAD
MRS ZARINA
MSD ARGENTINA S R L
PFIZER CHILE S A
PFIZER LIMITED
PHARMACIL LIMITED
RIZWANA FAWAD
SANOFI AVENTIS CHILE S A
SHIFA INTERNATIONAL HOSPITALS LIMITED
SULE MENE SAGLIK ARASTIRMA EGITIM DANISMANLIK BILISIM SANAYI TICARET ANONIM SIRKETI
SYNEOS HEALTH PERU S R L
ZYDUS LIFESCIENCES LIMITED
AMPLICON BIOTECH
ASIA SHAHRUKH
CAJA COSTARRICENSE DE SEGURO SOCIAL
DANVANTRI ENTERPRISES LIMITED
GSK PHARMA INDIA PRIVATE LIMITED
HETERO BIOPHARMA LIMITED
JANSSEN CILAG SA DE CV
KASHIV BIOSCIENCES PRIVATE LIMITED
KRISHGEN BIOSYSTEMS
MEDPACE MEXICO S DE RL DE CV
MR ABBAS HAIDER
MR AHMER GHAFFAR
MR JAHANZEB SOOMRO
MRS FARZANA BASHIR
MRS NOOR JEHAN
MRS NOOR UN NISA
MS FAZAILA EHSAN
MS SHAKEELA BIBI
MUHAMMAD ASHRAF
MUHAMMAD IQBAL
MUHAMMAD SHAHZAD
NULIFE CONSULTANTS AND DISTRIBUTORS PRIVATE LIMITE
NUZHAT MAHMOOD
RUKHSANA JAVAID
SABIRA BEGUM
SAEED AHMAD
SHABNAM RAFIQ
SHILPA BIOLOGICALS PRIVATE LIMITED
SIGMA ALDRICH CHEMICALS PRIVATE LIMITED
SYED HASSAN RAZA
SYNGENE INTERNATIONAL LTD
ADVANCED CHEMICAL INDUSTRIES LTD
AGA KHAN HOSPITAL AND MEDICAL COLLEGE FOUNDATION
ALIYA IMRAN
ARISTOPHARMA LTD CHANGE FROM
ASIFA NUZHAT
AURA MOSQUERA DIAZ DE MC FARLANE
BANGLADESH LABWARE CORPORATION
BF BIOSCIENCES LIMITED
BF BIOSCIENCESLIMITED
BIOCARD LOGISTICS DEPOT MSD
BIOCON BIOLOGICS LIMITED BSEZ UNIT
BIOGENE INDIA
BIONICHE LIMITED
BRISTOL MYERS SQUIBB DE CHILE
BRISTOL MYERS SQUIBB INDIA PRIVATE LIMITED
CCL PHARMACEUTICALS PVT LIMITED
ELI LILLY AND COMPANY INDIA PRIVATE LIMITED
EVERON LIFE SCIENCES
FATIMA KHALID
FORTREA TURKEY KLINIK ARASTIRMA LIMITED SIRKETI
GENIX PHARMA PRIVATE LIMITED
GENIX PHARMA PVT LTD
GENNOVA BIOPHARMACEUTICALS LIMITED
GLAXOSMITHKLINE ILACLARI SANAYI VE TICARET ANONIM SIRKETI
GLOBE BIOTECH LIMITED
HARLEYS T LIMITED
HIMMEL PHARMACEUTICALS PVT LIMITED
HIMMEL PHARMACEUTICALS PVT LTD
IBRAR UL HASSAN
IR INNOVATE RESEARCH PRIVATE LIMITED
IRASEMA ANAYANSI SANTAMARIA DELGADO DE BOSQUEZ
JOHNSON AND JOHNSON SIHHI MALZEME SANAYI VE TICARET LIMITED SIRKETI
M S PHARMEVO PVT LTD
MACTER INTERNATIONAL LIMITED
MACTER INTERNATIONAL LTD
MANKIND PHARMA LIMITED
MISHA GUL
MISS RUBINA RIAZ
MOIZE KASHMIRI
MR IJAZ AHMAD
MR M MSIDDIQUE
MR M SIDDIQUE
MR MUHAMMAD ANWAR
MR MUHAMMAD IQBAL
MR NADEEM WALI
MR PASHA JAFRI
MR ZAFAR IQBAL
MRS AMMARA DANISH
MRS ATIYA MUNAWWAR JAFFERY
MRS JAMZADI
MRS KANWAL AZEEM
MRS KHADIJA IRFAN
MRS MAHAM QAYYUM
MRS NOOR JAHAN
MRS RIFFAT IFTIKHAR
MRS SADIA SAEED
MRS SHAHEEN RASHEED
MRS WASYA ZULFIQAR AHMED
MSD PHARMACEUTICALS LLC
MUHAMMAD RASHID
MUHAMMAD USMAN
MUSARAT BIBI
NADEEM WALI
NAILA FAROOQ
NOOR PARI
ONCOPHARM U LTD
ONCOVANZ PHARMACEUTICALS PRIVATE LIMITED
PAREXEL INTERNATIONAL PERU S A
PASHA JAFRI
PHARMAGER S R L
PHARMAMED SOLUTION LIMITED
POPULAR PHARMACEUTICALS PLC
PPD MEXICO SA DE CV
PSM PHARMACEUTICALS LIMITED
RANA IMRAN RASHID
ROCHE CHILE LIMITADA
RUKHSANA JAVED
SHABINA MAHMOOD
SHANTAL SA
SHERISH SALEEM
SYED ISRAR HAIDER
SYED SALEEM HAIDER
SYNGENE INTERNATIONAL LIMITED
SYNGENE INTERNATIONAL LIMITED UNIT V
SYNGENE SCIENTIFIC SOLUTIONS LIMITED
THE ACME LABORATORIES LIMITED
USV PRIVATE LIMITED
WORLD COURIER INC
ГУ ЦЕНТР БЕЗОПАСНОСТИ ФАРМАЦЕВТИЧЕСКОЙ ПРОДУКЦИИ
ООО АЛЬГИМЕД
ТОО КАРАГАНДИНСКИЙ ФАРМАЦЕВТИЧЕСКИЙ КОМПЛЕКС

Conclusion

The global pembrolizumab procurement landscape encompasses a diverse and growing network of buyers spanning hospitals, government health systems, specialty pharmacies, and pharmaceutical distributors across more than 60 countries. From the Maldives’ INDIRA GANDHI MEMORIAL HOSPITAL to Brazil’s expanding public procurement programs, from India’s MSD PHARMACEUTICALS PRIVATE LIMITED to Saudi Arabia’s Avalon Pharma, the buyer ecosystem reflects the drug’s status as a cornerstone of modern oncology.

As the 2028 patent cliff approaches, the procurement landscape will undergo significant transformation. Biosimilar market entry will create new opportunities for supplier diversification and pricing optimization, while expanding indications and new formulations will sustain robust demand. For procurement professionals, strategic intelligence—including up-to-date buyer lists, trade flow analysis, and biosimilar pipeline tracking—will be essential for navigating this dynamic market.

Disclaimer: This article is for informational purposes only. All trade data is derived from publicly available customs records and may not reflect complete market activity. Buyers and suppliers should verify all information through official channels and consult with qualified legal and regulatory advisors for procurement decisions.

Table of Contents